Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Vanhove T et al. | Comparative performance of oral midazolam clearance and plasma 4β-hydroxycholesterol to explain interindividual variability in tacrolimus clearance. | 2016 | Br J Clin Pharmacol | pmid:27501475 |
Aubry AF et al. | Recommendations on the Development of a Bioanalytical Assay for 4β-Hydroxycholesterol, an Emerging Endogenous Biomarker of CYP3A Activity. | 2016 | AAPS J | pmid:27350147 |
Ishida T et al. | Relationship between the plasma fentanyl and serum 4β-hydroxycholesterol based on CYP3A5 genotype and gender in patients with cancer pain. | 2016 | Drug Metab. Pharmacokinet. | pmid:27236640 |
Xue YJ et al. | Use of 4β-hydroxycholesterol in animal and human plasma samples as a biomarker for CYP3A induction. | 2016 | Bioanalysis | pmid:26805594 |
Mao J et al. | Strategy for CYP3A Induction Risk Assessment from Preclinical Signal to Human: a Case Example of a Late-Stage Discovery Compound. | 2017 | Pharm. Res. | pmid:28815392 |
Gjestad C et al. | 4β-Hydroxycholesterol level significantly correlates with steady-state serum concentration of the CYP3A4 substrate quetiapine in psychiatric patients. | 2017 | Br J Clin Pharmacol | pmid:28585378 |
Jiang X et al. | An Exposure-Response Modeling Approach to Examine the Relationship Between Potency of CYP3A Inducer and Plasma 4β-Hydroxycholesterol in Healthy Subjects. | 2017 | Clin Pharmacol Drug Dev | pmid:27138546 |
Wollmann BM et al. | 4β-Hydroxycholesterol Level in Patients With Rheumatoid Arthritis Before vs. After Initiation of bDMARDs and Correlation With Inflammatory State. | 2017 | Clin Transl Sci | pmid:27991741 |
Hole K et al. | Impact of genetic and nongenetic factors on interindividual variability in 4β-hydroxycholesterol concentration. | 2017 | Eur. J. Clin. Pharmacol. | pmid:27975131 |
Oh J et al. | Effects of renal impairment on the pharmacokinetics and pharmacodynamics of a novel dipeptidyl peptidase-4 inhibitor, evogliptin (DA-1229). | 2017 | Diabetes Obes Metab | pmid:27761990 |
Mao J et al. | Perspective: 4β-hydroxycholesterol as an emerging endogenous biomarker of hepatic CYP3A. | 2017 | Drug Metab. Rev. | pmid:27718639 |
Størset E et al. | The CYP3A biomarker 4β-hydroxycholesterol does not improve tacrolimus dose predictions early after kidney transplantation. | 2017 | Br J Clin Pharmacol | pmid:28146606 |
Vanhove T et al. | Pretransplant 4β-hydroxycholesterol does not predict tacrolimus exposure or dose requirements during the first days after kidney transplantation. | 2017 | Br J Clin Pharmacol | pmid:28603840 |